Cyclacel Pharmaceuticals Valuation
| CYCCP Preferred Stock | USD 6.75 0.19 2.74% |
At this time, the firm appears to be overvalued. Cyclacel Pharmaceuticals shows a prevailing Real Value of $5.9 per share. The current price of the firm is $6.75. Our model approximates the value of Cyclacel Pharmaceuticals from analyzing the firm fundamentals such as return on equity of -0.6, and Current Valuation of 24.42 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cyclacel Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Cyclacel Pharmaceuticals is based on 3 months time horizon. Increasing Cyclacel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cyclacel Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 6.75, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.75 | Real 5.9 | Hype 6.75 | Naive 7.24 |
The intrinsic value of Cyclacel Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cyclacel Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cyclacel Pharmaceuticals helps investors to forecast how Cyclacel preferred stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyclacel Pharmaceuticals more accurately as focusing exclusively on Cyclacel Pharmaceuticals' fundamentals will not take into account other important factors: Cyclacel Pharmaceuticals Total Value Analysis
Cyclacel Pharmaceuticals is currently forecasted to have takeover price of 24.42 M with market capitalization of 23.14 M, debt of 113 K, and cash on hands of 29.08 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cyclacel Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.42 M | 23.14 M | 113 K | 29.08 M |
Cyclacel Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Cyclacel is to check how much profit was generated for every dollar of assets it reports. Cyclacel Pharmaceuticals shows a negative utilization of assets of -0.42 percent, losing $0.004167 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cyclacel Pharmaceuticals shows how unproductive it operates for each dollar spent on its assets.Cyclacel Pharmaceuticals Ownership Allocation
The market capitalization of Cyclacel Pharmaceuticals is $23.14 Million. Almost 99.53 percent of Cyclacel Pharmaceuticals outstanding shares are held by general public with 0.47 (percent) owned by insiders and only 0.0 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Cyclacel Pharmaceuticals Profitability Analysis
Net Loss for the year was (18.89 M) with loss before overhead, payroll, taxes, and interest of (338 K).About Cyclacel Pharmaceuticals Valuation
The preferred stock valuation mechanism determines Cyclacel Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cyclacel Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclacel Pharmaceuticals. We calculate exposure to Cyclacel Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cyclacel Pharmaceuticals's related companies.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
8 Steps to conduct Cyclacel Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cyclacel Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cyclacel Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cyclacel Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cyclacel Pharmaceuticals' revenue streams: Identify Cyclacel Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cyclacel Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cyclacel Pharmaceuticals' growth potential: Evaluate Cyclacel Pharmaceuticals' management, business model, and growth potential.
- Determine Cyclacel Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cyclacel Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cyclacel Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cyclacel Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.9 M | |
| Retained Earnings | -385 M |
Additional Tools for Cyclacel Preferred Stock Analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.